NEA Management Company’s Cascadian Therapeutics, Inc. CASC Stock Holding History

NEA Management Company’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-9,064,575	Closed	-$33.5M	–	45
2017 Q4	$33.5M	Hold	9,064,575	–	–	1.39%	17
2017 Q3	$37.1M	Hold	9,064,575	–	–	1.3%	16
2017 Q2	$33.7M	Hold	9,064,575	–	–	1.23%	17
2017 Q1	$37.5M	Buy	9,064,575 +7,272,909	+406%	+$30.6M	1.31%	13
2016 Q4	$7.72M	Sell	1,791,666 -1	-0%	-$6	0.31%	23
2016 Q3	$17.6M	Hold	1,791,667	–	–	0.79%	19
2016 Q2	$10.1M	Buy	+1,791,667	New	+$12.2M	0.52%	21

NEA Management Company's CASC Position: Q1 2018 in Review

NEA Management Company sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 9,064,575 shares — an estimated $33.5M sold.

NEA Management Company first reported a position in CASC in Q2 2016 and held it in 7 quarters. The position peaked at $37.5M in Q1 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

NEA Management Company reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
NEA Management Company sold 9,064,575 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $33.5M.
NEA Management Company first reported a position in Cascadian Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
NEA Management Company's Cascadian Therapeutics, Inc. position peaked at $37.5M in Q1 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on NEA Management Company's 13F filing for Q1 2018, filed 10 May 2018.